Table 2.
Univariate and Multivariate Regression Analysis
| Parameter | UV HR (95% CI) | UV p | MV HR (95% CI) | MV p* |
|---|---|---|---|---|
| Progression-free survival | ||||
| BEV usage | 0.676 (0.496–0.921) | 0.013 | 0.789 (0.653–0.954) | 0.014* |
| BEV cycles | 0.934 (0.910–0.958) | <0.001 | 1.534 (1.045–2.253) | 0.029* |
| TMZ cycles | 0.816 (0.785–0.848) | <0.001 | 0.840 (0.803–0.879) | <0.001* |
| IDH | 1.414 (1.018–1.965) | 0.039 | ||
| MGMT | 1.928 (1.362–2.729) | <0.001 | ||
| Reoperation | 3.524 (2.359–5.263) | <0.001 | 2.123 (1.427–3.160) | <0.001* |
| Pathological grade | 1.662 (1.196–2.309) | 0.002 | 1.579 (1.103–2.259) | 0.013* |
| Reoperation to BEV | 0.872 (0.769–0.988) | 0.032 | ||
| Overall survival | ||||
| BEV cycles | 0.942 (0.920–0.965) | <0.001 | ||
| TMZ cycles | 0.722 (0.691–0.756) | <0.001 | 0.729 (0.693–0.767) | <0.001* |
| IDH | 1.582 (1.133–2.208) | 0.007 | ||
| MGMT | 1.891 (1.328–2.691) | <0.001 | ||
| Reoperation | 3.789 (2.536–5.661) | <0.001 | 2.325 (1.544–3.501) | <0.001* |
| Pathological grade | 1.665 (1.195–2.321) | 0.003 | ||
| KPS | 0.988 (0.978–0.998) | 0.023 |
Notes: * indicates p-value < 0.05.
Abbreviations: UV, univariable; MV, multivariable; CI, confidence interval; HR, hazard ratio; BEV, bevacizumab; TMZ, Temozolomide; KPS, karnofsky performance score.